research Yangxuebushen Decoction prevents cyclophosphamide-induced hair loss by inhibiting hair follicle apoptosis
Yangxuebushen Decoction helps prevent hair loss from chemotherapy.
Search
for
Sort by
Research
450-480 / 1000+ results
research Combination Therapy with 308-nm Excimer Laser, Compound Glycyrrhizin, and Tacrolimus for Pediatric Facial and Cervical Vitiligo
The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.
research Molecular Mechanism of Avicennia marina (Forssk.) Vierh. in Inhibiting Hepatitis C Virus Based on Network Pharmacology and Molecular Docking
Avicennia marina shows potential to treat Hepatitis C by targeting key proteins.
research Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata
research Review of Promising Off-Label Use of Deucravacitinib
Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
research UTMD Enhances Targeting of Diclofenac and Doxil® to Boost Tumor Immunotherapy
UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.
research Biological therapy in the treatment of melanoma
Biological therapy boosts the immune system to effectively fight melanoma.
research LB1007 Systemic treatment with a KLK5 inhibitor shows efficacy in a murine model of Netherton syndrome
A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.
research Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment
Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.
research Changes in distribution pattern of CD8 lymphocytes in the scalp in alopecia areata during treatment with diphencyprone
Diphencyprone treatment increases CD8 lymphocytes in the scalp, which is associated with hair regrowth in alopecia areata patients.
research 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
CTP-543 is generally safe for treating alopecia areata.
research Taming of Covid-19: potential and emerging application of mesenchymal stem cells
Mesenchymal stem cells show promise in treating COVID-19 by reducing inflammation and aiding recovery, but more research is needed.
research 15460 Perifollicular pink halo: A potential dermoscopic marker of inflammation in central centrifugal cicatricial alopecia
Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
research Case Report: Multimodal contact immunotherapy in alopecia areata: long-term clinical experience in the JAK inhibitor era
Topical immunotherapy is still effective for managing alopecia areata, even with new treatments available.
research Immune Cell-Targeting Biologics for Alopecia Areata: A New Paradigm in Precision Medicine
Immune cell-targeting biologics show potential for treating alopecia areata but need better-targeted therapies.
research The role of janus kinases in the treatment of autoimmune skin diseases
Janus kinase inhibitors show promise in treating autoimmune skin diseases.
research PROTECTION AGAINST CYTOSINE ARABINOSIDE-INDUCED ALOPECIA BY MINOXIDIL IN A RAT ANIMAL MODEL
Minoxidil helps prevent hair loss from chemotherapy in rats.
research Major improvement of very severe alopecia areata in patients treated with the combination of baricitinib and low doses of corticosteroids: an eight-case series
Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.
research Present Chemotherapy Induced Alopecia and Research in Future
Current treatments for hair loss from chemotherapy are limited, but new methods are being researched.
research INIBIDORES DA JANUS QUINASE PARA O TRATAMENTO DA ALOPECIA AREATA
JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
research Abstract P1-09-32: A novel candidate for chemotherapy induced alopecia (CIA) through local modulation of apoptosis and inflammation
A new treatment may prevent hair loss from chemotherapy by normalizing scalp cell death and reducing inflammation.
research Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
research A phase 2a trial of brepocitinib for cicatricial alopecia
Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
research Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
Blocking Janus kinase 1 helps stop inflammation and regrow hair, making it a good treatment for hair loss from alopecia areata.
research Folate-cyclodextrin Conjugate for Targeted Chemotherapy
The folate-cyclodextrin conjugate targets cancer cells more precisely, potentially reducing chemotherapy side effects.
research High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata
CD8+ T cells are involved in alopecia areata and may cause disease relapse.
research Topical cyclosporin A treatment in psoriasis and other dermatological diseases: Theoretical and practical aspects
Topical cyclosporin A may help treat psoriasis but has absorption and side effect challenges.
research JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
Baricitinib shows promise for treating alopecia areata with mild side effects.
research 478 Mutation-specific siRNA Knockdown of GJB2 − Potential gene therapy for Keratitis-ichthyosis-deafness Syndrome
Targeted siRNA therapy may be a promising treatment for KID syndrome by reducing mutant gene expression and improving cell communication.
research Toll-like Receptor 3 Agonist, Polyinosinic-polycytidylic Acid, Upregulates Carbonic Anhydrase II in Human Keratinocytes
A substance called poly(I:C) increases a protein called carbonic anhydrase II in skin cells, which might help with skin defense and healing.